These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 16819291

  • 1. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer.
    Kang S, Ju W, Kim JW, Park NH, Song YS, Kim SC, Park SY, Kang SB, Lee HP.
    Exp Mol Med; 2006 Jun 30; 38(3):320-4. PubMed ID: 16819291
    [Abstract] [Full Text] [Related]

  • 2. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL, Li Y, Wang N, Zhou RM, Hu P, Kang S.
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov 30; 48(11):847-52. PubMed ID: 24444563
    [Abstract] [Full Text] [Related]

  • 3. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
    Moxley KM, Benbrook DM, Queimado L, Zuna RE, Thompson D, McCumber M, Premkumar P, Thavathiru E, Hines L, Moore KN.
    Gynecol Oncol; 2013 Aug 30; 130(2):377-82. PubMed ID: 23632208
    [Abstract] [Full Text] [Related]

  • 4. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
    Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, DeLoia JA, Gynecologic Oncology Group Phase III Trial.
    J Clin Oncol; 2008 Jul 20; 26(21):3598-606. PubMed ID: 18640939
    [Abstract] [Full Text] [Related]

  • 5. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
    Steffensen KD, Waldstrøm M, Jeppesen U, Brandslund I, Jakobsen A.
    Int J Gynecol Cancer; 2008 Jul 20; 18(4):702-10. PubMed ID: 17961161
    [Abstract] [Full Text] [Related]

  • 6. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D.
    J Clin Oncol; 2007 Nov 20; 25(33):5172-9. PubMed ID: 18024864
    [Abstract] [Full Text] [Related]

  • 7. Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.
    Li Y, Hu P, Cao Y, Wang GY, Wang N, Zhou RM.
    Biomarkers; 2014 Mar 20; 19(2):128-34. PubMed ID: 24499239
    [Abstract] [Full Text] [Related]

  • 8. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC.
    Clin Cancer Res; 2004 Aug 01; 10(15):4939-43. PubMed ID: 15297394
    [Abstract] [Full Text] [Related]

  • 9. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
    Kuhlmann JD, Wimberger P, Bankfalvi A, Keller T, Schöler S, Aktas B, Buderath P, Hauch S, Otterbach F, Kimmig R, Kasimir-Bauer S.
    Clin Chem; 2014 Oct 01; 60(10):1282-9. PubMed ID: 25015375
    [Abstract] [Full Text] [Related]

  • 10. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
    Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer M, Krivak TC.
    Gynecol Oncol; 2012 May 01; 125(2):421-6. PubMed ID: 22261301
    [Abstract] [Full Text] [Related]

  • 11. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
    Liblab S, Vusuratana A, Areepium N.
    Asian Pac J Cancer Prev; 2020 Jul 01; 21(7):1925-1929. PubMed ID: 32711417
    [Abstract] [Full Text] [Related]

  • 12. [ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].
    Bogush TA, Popova AS, Dudko EA, Bogush EA, Tyulyandina AS, Tyulyandin SA, Davydov MI.
    Antibiot Khimioter; 2015 Jul 01; 60(3-4):42-50. PubMed ID: 26415382
    [Abstract] [Full Text] [Related]

  • 13. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS.
    Lung Cancer; 2004 Jun 01; 44(3):311-6. PubMed ID: 15140544
    [Abstract] [Full Text] [Related]

  • 14. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.
    Am J Clin Oncol; 2010 Oct 01; 33(5):489-94. PubMed ID: 20351547
    [Abstract] [Full Text] [Related]

  • 15. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
    Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ.
    Clin Adv Hematol Oncol; 2003 Mar 01; 1(3):162-6. PubMed ID: 16224397
    [Abstract] [Full Text] [Related]

  • 16. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
    Steffensen KD, Smoter M, Waldstrøm M, Grala B, Bodnar L, Stec R, Szczylik C, Jakobsen A.
    Int J Oncol; 2014 May 01; 44(5):1736-44. PubMed ID: 24585004
    [Abstract] [Full Text] [Related]

  • 17. Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort.
    Bao Y, Yang B, Zhao J, Shen S, Gao J.
    Int J Immunogenet; 2020 Oct 01; 47(5):443-453. PubMed ID: 32173978
    [Abstract] [Full Text] [Related]

  • 18. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
    Deloia JA, Bhagwat NR, Darcy KM, Strange M, Tian C, Nuttall K, Krivak TC, Niedernhofer LJ.
    Gynecol Oncol; 2012 Sep 01; 126(3):448-54. PubMed ID: 22609620
    [Abstract] [Full Text] [Related]

  • 19. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM, Tian C, Reed E.
    Cancer Res; 2007 May 01; 67(9):4474-81. PubMed ID: 17483363
    [Abstract] [Full Text] [Related]

  • 20. Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis.
    Tang N, Lyu D, Zhang Y, Liu H.
    BMC Womens Health; 2017 Jun 17; 17(1):43. PubMed ID: 28623887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.